With AMR-related deaths estimated to rise from 322,000 in 2021 to 650,000 by 2050, Latin America and the Caribbean is expected to be among the regions with the highest AMR mortality rates across all ages. But by acting together now we can help change that. We are very pleased to announce that we will collaborate with the Pan American Health Organization in the response to antimicrobial resistance (AMR) in Latin America and the Caribbean. Under the agreement, PAHO and GARDP aim to improve regional antibiotic R&D, manufacturing and access in the context of the emergence and spread of antibiotic-resistant infections. These efforts are in line with GARDP’s 2024-2028 strategy, now available in Spanish and Portuguese Read the press release: https://lnkd.in/dDuJQWTN Leia a estratégia 2024-2028 da GARDP: https://lnkd.in/dEQpc96k Lea la estrategia 2024-2028 de GARDP: https://lnkd.in/dFUDPnCD #Partnerships #AMR #LAC #AntibioticResistance Jarbas Barbosa Dr Manica Balasegaram
Global Antibiotic R&D Partnership (GARDP)
Forschungsdienstleistungen
Geneva, Switzerland 22.580 Follower:innen
Putting public health needs at the centre of antibiotic drug development to address the crisis of AMR
Info
The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit organization that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health, and makes them accessible to the people who need them. It puts public health needs at the centre of antibiotic drug development to address both the immediate antimicrobial resistance (AMR) crisis and to ensure people continue to get access to essential antibiotics for generations to come. GARDP works through a global network including Brazil, India, Japan, and South Africa for antibiotic development and access. Its work is made possible by essential funding from donors and collaboration with over 100 R&D and access partners in over 20 countries. GARDP was created by the World Health Organization and the Drugs for Neglected Diseases initiative (DNDi) in 2016 and legally registered as the GARDP Foundation in Geneva, Switzerland in 2018. www.gardp.org
- Website
-
http://www.gardp.org
Externer Link zu Global Antibiotic R&D Partnership (GARDP)
- Branche
- Forschungsdienstleistungen
- Größe
- 51–200 Beschäftigte
- Hauptsitz
- Geneva, Switzerland
- Art
- Nonprofit
- Gegründet
- 2016
- Spezialgebiete
- Antibiotic resistance, antibiotic drug development, R&D partnerships, serious bacterial infections, children’s antibiotics, sexually transmitted infections, global health, public health, pandemic preparedness, antibiotic access, sepsis and neonatal sepsis und gonorrhoea
Orte
-
Primär
Chemin Louis-Dunant 15
Geneva, Switzerland 1202, CH
Beschäftigte von Global Antibiotic R&D Partnership (GARDP)
Updates
-
We're hiring! Join our diverse, dynamic team tackling Antibiotic Resistance. Check out our latest vacancies and apply now: https://lnkd.in/eczPVzZy Know someone who’d be a great fit? Share! #jobopening #vacancies #careeropportunities
-
The fight against antimicrobial resistance (AMR) took center stage last week at the United Nations General Assembly, with world leaders and health organizations raising the alarm on this escalating global crisis. Read more on the critical need for coordinated action across borders in The New York Times, with Dr Manica Balasegaram: https://lnkd.in/d2TKfkNv #AMR #GlobalHealth #UNGA79 #AntibioticResistance #PublicHealth
-
Registrations and Abstract submissions are now open for the Antimicrobial Chemotherapy Conference 2025! ACC2025 is an open-access, virtual conference jointly organized by the British Society for Antimicrobial Chemotherapy (BSAC) and GARDP. This year, the Antimicrobial Chemotherapy Conference is being held in collaboration with Cepid Aries and Fiocruz. 📆 4&5 February 2025 🎟️ Register now for free: https://lnkd.in/ghYJws8w #ACC2025 #PowerofAntibiotics #AMR
Dieser Inhalt ist hier nicht verfügbar.
Mit der LinkedIn App können Sie auf diese und weitere Inhalte zugreifen.
-
Collaboration is essential in the fight against antimicrobial resistance (AMR). “If you look at countries who’ve really had problems with AMR, the work that some of these NGOs are doing around collecting the data on resistance and working with us on how to manufacture the antibiotics, is the way forward. So it’s got to be a combined effort of pharma companies, governments, NGOs working together across all countries to make this happen and to try and solve this problem” Andreas Karas, MD, Head of Scientific Affairs, Shionogi Europe Through our project with Shionogi, we aim to forge new pathways and build sustainable networks so that cefiderocol—and, in the future, other antibiotics like it—can reach people in need. Watch now: https://lnkd.in/dcqhiFnH #AMR #AntimicrobialResistance #Collaboration #GlobalHealth #Pharma
Antimicrobial resistance (AMR) knows no borders. People everywhere suffer from drug-resistant infections, but the burden is especially great in low- and middle-income countries, where legal and regulatory barriers often hinder access to new antibiotics. Shionogi has led the industry in forging partnerships with the Global Antibiotic R&D Partnership (GARDP) and the Clinton Health Access Initiative, Inc. (CHAI) to significantly transform access to antibiotics for countries around the world. As part of a new Shionogi sponsored programme, Defending our Health: Unravelling Antimicrobial Resistance, produced by ITN Business, Shionogi Europe's Head of Scientific Affairs, Dr Andreas Karas, MD, discussed our commitment to supporting equitable access to antibiotics and combating drug-resistant infection through our work with strategic partners. No single organisation alone can tackle AMR. Let’s act together for sustainable solutions! Find out more here: https://lnkd.in/e-KcCs95 #AMRAwareness #AntimicrobialResistance
-
We are proud to announce Prof Glenda Gray as the Chair of our GARDP Board of Directors, and Dr Bernard Pécoul as Vice-Chair. Together with board members, they will oversee GARDP’s mandate to develop and deliver treatments for drug-resistant infections. Prof Gray is a distinguished scientist who has led the South African Medical Research Council (SAMRC) for two five-year terms. Dr Pécoul founded the Drugs for Neglected Diseases initiative - DNDi. Under his guidance from 2003 until 2022, DNDi delivered 12 new treatments for six deadly diseases. GARDP is very grateful to our outgoing Board chair, Dr Ramanan Laxminarayan. During his term, GARDP has made significant progress towards establishing the global ecosystem needed to address antimicrobial resistance. “Prof Gray brings a wealth of experience in public health and innovation and has led efforts in collaborative research to address pressing health challenges in South Africa and globally.” Dr Manica Balasegaram, Executive Director of GARDP. Learn more: https://lnkd.in/dED_yf78 #AMR #Board #Announcement #AntibioticResistance
-
Antimicrobial resistance (AMR) will force millions into poverty. Over the next decade, antibiotic resistance could force an additional 24 million people, like Momipal, into medical impoverishment. The race is on, and we all have a role to play in mitigating this crisis. Learn more and raise your voice: https://lnkd.in/dw5zf_J5
-
We're hiring! Join a multicultural and dynamic team committed to addressing the growing threat of antibiotic resistance. Click on the link to find our new vacancies: https://lnkd.in/eczPVzZy Share it with your network! #jobopening #vacancies #careeropportunities #AntibioticResistance
-
Antimicrobial resistance (AMR) will force millions into poverty. Over the next decade, antibiotic resistance could force an additional 24 million people, like Momipal, into medical impoverishment. The race is on, and we all have a role to play in mitigating this crisis. Learn more and raise your voice: https://lnkd.in/dw5zf_J5
-
We applaud Member States for the successful adoption of the second High-Level Political Declaration on antimicrobial resistance (AMR) and its recognition of GARDP’s mission and its partners to support both antibiotic research and development, and equitable and sustainable access to them for all people in need. We hope that this will provide Member States, researchers, not-for-profit partnerships, the private sector and civil society with a positive way forward to maintain and build upon our collective efforts, turning words into action to address this escalating global AMR crisis. The commitments enshrined in the Declaration, acknowledge the “benefits of public-private partnerships in the development of and access to antimicrobials”, including the work of GARDP. It calls on all parties to work in collaboration, including with GARDP, the SECURE initiative (which we co-host), and with the Global Drug Facility, “to take steps to increase global access to and appropriate use of antimicrobials in settings with the highest unmet need.” During this last week, we called attention to the problems we are trying to solve, and our progress with our partners, through an intervention during the High-Level Meeting, through an event we co-hosted with Foreign Policy, and through our participation in many other meetings and events held by our partners. We were also pleased to announce new funding from existing and new public and private donors, to ensure GARDP can meet the needs of all people suffering from drug-resistant infections. #UNGA79 #AMR #AntibioticResistance #PowerOfAntibiotics
-
9